Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-06-13 Director's Dealing
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 23 - 2023
Director's Dealing Classification · 1% confidence The document text consists of tables detailing transactions involving the issuer 'IPSEN'. The tables include columns like 'Jour de la transaction' (Date of transaction), 'Volume total journalier (en nombre d'actions)' (Total daily volume in number of shares), 'Prix pondéré moyen journalier d'acquisition des actions' (Daily weighted average acquisition price), and a second table detailing 'Quantité achetée' (Quantity bought) by specific parties ('Nom du PSI'). This structure is characteristic of mandatory disclosures regarding insider trading or significant share transactions by directors or major shareholders. Comparing this to the definitions, 'Director's Dealing' (DIRS) covers personal share transactions by directors, and 'Major Shareholding Notification' (MRQ) covers changes in significant share ownership. Since the data shows daily transaction volumes and prices, often associated with insider activity or share repurchase programs, it strongly aligns with insider transaction reporting. The presence of 'Nom du PSI' (Name of the PSI - probably referring to a specific trading entity or person involved in the transaction) and the detailed transaction logs point towards reporting of personal dealings or transactions by related parties. Given the options, 'Director's Dealing' (DIRS) is the most appropriate fit for detailed transaction logs by insiders, although 'Transaction in Own Shares' (POS) could apply if these were buybacks, but the structure suggests reporting of individual trades by specific entities/persons. Since the data explicitly lists transactions by 'Exane SA' (a likely related party or insider) with quantities bought, DIRS is the best classification for insider transaction reporting.
2023-06-13 French
Ipsen présentera lors du Congrès EASL 2023 de nouvelles données cliniques et les résultats d’outils d'évaluation par les patients issus de son portefeuille croissant dans les maladies rares du foie
Regulatory Filings Classification · 1% confidence The document is a press release dated June 12, 2023, announcing that Ipsen will present new clinical data and patient-reported outcome tool results from its rare liver disease portfolio at the EASL 2023 Congress. It details specific abstracts, poster presentations, and oral presentations related to their drug Bylvay® and other assets. This type of announcement, detailing upcoming scientific presentations at a conference, is characteristic of an Investor Presentation (IP) or a general corporate/investor relations update, rather than a formal regulatory filing (like 10-K, AR, or ER). Since it is a detailed announcement about data being presented to investors/scientists at a specific event, Investor Presentation (IP) is the most fitting category, as it often precedes or accompanies investor briefings on research progress.
2023-06-12 French
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Environmental & Social Information Classification · 1% confidence The document is a press release from Ipsen announcing that they will present new clinical data on their rare liver disease portfolio at the EASL 2023 Congress. It details the abstracts, poster presentations, and oral presentations scheduled for the conference, including specific dates and times (June 21-24, 2023). This type of announcement, detailing upcoming scientific presentations or the publication of research findings at a conference, is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a communication aimed at investors and the scientific community about ongoing research progress. Since it is an announcement about data being presented at a scientific meeting, and not the full financial report (10-K, IR), earnings release (ER), or a formal regulatory filing (RNS), it aligns closely with the purpose of an Investor Presentation (IP) which often includes pipeline updates and clinical trial data summaries, or potentially a Regulatory Filing (RNS) if it were a general announcement. Given the detailed breakdown of scientific presentations and trial data summaries, 'Investor Presentation' (IP) is a strong fit, as these materials often precede or accompany formal presentations to investors. However, since it is an announcement *about* presentations rather than the presentation deck itself, and it is a general corporate update, 'Regulatory Filings' (RNS) serves as a broad category for non-standard corporate communications. Given the context of presenting clinical data, 'Investor Presentation' (IP) is the most specific fit for the *content* being highlighted, even if the format is a press release announcing the event.
2023-06-12 English
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information relative to the total number of voting rights and shares composing the share capital' and explicitly references compliance with French Commercial Code and AMF regulations. It provides a table detailing the total number of shares and the total number of voting rights as of May 31, 2023. This type of periodic disclosure regarding the capital structure and voting rights is most closely aligned with notifications concerning major shareholdings or capital structure changes, but given the specific focus on the total number of voting rights and shares, it fits best under the category related to significant ownership changes or capital structure reporting. Since there is no specific code for 'Monthly Voting Rights Disclosure', I must choose the closest fit. 'Major Shareholding Notification' (MRQ) covers changes in significant share ownership levels, which often necessitates these periodic updates. However, the content is a direct disclosure of the capital structure itself, not necessarily a notification of a *change* crossing a threshold by a specific entity, but rather a mandatory monthly update on the total structure. Given the options, 'Major Shareholding Notification' (MRQ) is the most appropriate category for disclosures related to the total voting rights base, as these figures are crucial for calculating ownership thresholds. If MRQ is too specific to threshold crossing, 'Share Issue/Capital Change' (SHA) is also plausible, but this is a reporting requirement, not an announcement of a new issue. I will select MRQ as it relates directly to the mechanics of voting rights and share capital reporting required for major shareholders.
2023-06-09 English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and total gross/net voting rights as of May 31, 2023. This content directly relates to reporting changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA), as it is a mandatory periodic disclosure concerning the share capital base.
2023-06-09 French
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 22 - 2023
Director's Dealing Classification · 1% confidence The document contains detailed tables showing transactions involving the issuer 'IPSEN' and a reporting entity 'Exane SA' (likely a broker or investment firm). The tables list 'Jour de la transaction' (Date of transaction), 'Volume total journalier' (Total daily volume), 'Prix pondéré moyen journalier d'acquisition' (Weighted average acquisition price), and specific transaction details including 'Quantité achetée' (Quantity bought) and 'Prix Unitaire' (Unit Price). This structure is characteristic of mandatory disclosures regarding personal share transactions by directors, executives, or major shareholders, often referred to as insider trading reports or director's dealings. Reviewing the definitions, 'Director's Dealing (Code: DIRS)' fits this description best, as it covers 'Report of personal share transactions by company directors and executives (insider trades)'. The data clearly details share transactions (buying/selling) by an entity associated with the company.
2023-06-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.